Geneva, May 4 -- International Clinical Trials Registry received information related to the study (DRKS00039240) titled 'ROAD: Retrospective Analysis of Ocrelizumab Use in Older Adults: A Real-World Data Analysis' on April 22.
Study Type: observational
Study Design:
Allocation:
Masking:
Control:
Assignment:
Study design purpose: treatment
Primary Sponsor: Roche Pharma AG
Condition:
G35.1
Relapsing multiple sclerosis
Intervention:
Group 1: Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system affecting more than 2.8 million people worldwide and remaining the leading cause of non-traumatic disability in young adults. While MS typically has an onset in younger individuals, improved disease-modify...